NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=169625&from=3 CLASS PERIOD: March 4, 2024 to May ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=169614&from=4 ...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (the "Company†) (Nasdaq: SVRA), a clinical- stage biopharmaceutical company focused on rare respiratory diseases, today announced additional analyses from its pivotal Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP were presented as poster presentations at the ERS Congress 2025 in Amsterdam, The Netherlands. ERS 2025 Posters Savara Title: Efficacy of Inhaled Molgramostim According to Severity of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). ...

Accessibility StatementSkip Navigation BENSALEM, Pa., Sept. 26, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Savara Inc. ("Savara" or the "Company") (NASDAQ: SVRA). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SAVARA (SVRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE NOVEMBER 7, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 26, 2025 /PRNewswire/ -- Levi &Â Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/ ...

诉讼核心信息 - DJS Law Group提醒投资者针对Savara Inc (NASDAQ: SVRA) 提起集体诉讼 指控其违反1934年证券交易法的第10(b)条和第20(a)条以及美国证券交易委员会制定的10b-5规则 [1] - 集体诉讼期定义为2024年3月7日至2025年5月23日 申请担任首席原告的截止日期为2025年11月10日 [2] 指控内容 - 指控公司在集体诉讼期间作出虚假和误导性陈述 [2] - 指控公司向美国FDA提交的MOLBREEVI生物制剂许可申请包含不充分信息 特别是未能提供化学和制造方面的细节 [2] - 基于这些缺陷 美国FDA不太可能批准该BLA [2]

LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR SAVARA INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOU ...

https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=168877&from=4 CLASS PERIOD: March 4, 2024 to May 23, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) MOLBREEVI BLA, the treatment of pulmonary alveolar proteinosis, lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MO ...

公司核心事件 - 律师事务所Robbins LLP提醒投资者，一项集体诉讼已代表在2024年3月7日至2025年5月23日期间购买或收购Savara Inc (NASDAQ: SVRA) 证券的个人和实体提起 [1] - Savara Inc是一家专注于罕见呼吸系统疾病的临床阶段生物制药公司，其主要候选产品是MOLBREEVI（也称为molgramostim），一种吸入式粒细胞-巨噬细胞集落刺激因子 [1] 诉讼指控内容 - 指控称，在公司期间，管理层未能披露MOLBREEVI的生物制剂许可申请缺乏关于其化学、制造和控制的足够信息 [2] - 指控还称，因此美国FDA不太可能以当前形式批准MOLBREEVI的BLA，这使得公司不太可能在其向投资者承诺的时间框架内完成BLA的提交 [2] - 指控进一步指出，MOLBREEVI监管批准的延迟增加了公司需要筹集额外资金的可能性 [2] 股价影响与市场反应 - 2025年5月27日，公司发布新闻稿宣布收到FDA的拒绝提交函，FDA初步审查后确定MOLBREEVI的BLA不够完整，无法进行实质性审查，并要求提供更多CMC相关数据 [3] - 受此消息影响，Savara的股价在2025年5月27日下跌每股0.90美元，跌幅达31.69%，报收于每股1.94美元 [3] 诉讼程序相关信息 - 希望担任集体诉讼首席原告的股东必须在2025年11月7日前向法院提交文件 [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Savara To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 Â (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept. ...